Aim 3, Adapting and Implementing Evidence-based Breast Cancer Follow-up in Primary Care
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · May 27, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Aim 3 is a hybrid type 1 effectiveness-implementation cluster randomized study with a waitlist control in 26 primary care practices. This study uses a tailored combination of practice facilitation, expert consultation, collaborative learning events, and audit and feedback as intervention strategies, and a mixed-methods comparative case study learning evaluation for primary care practices to adapt priority recommendations of evidence-based activities for breast cancer survivorship care. Intervention effectiveness will be assessed in two groups of clinics: 13 cases that will receive the imple...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Self-identification as a staff member or patient who has had breast cancer in a participating practice
- Exclusion Criteria:
- • Unable to speak, understand and/or read English
- • Unable to provide informed consent
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Brunswick, New Jersey, United States
Patients applied
Trial Officials
Shawna V Hudson, PhD
Principal Investigator
Rutgers University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials